<?xml version="1.0" encoding="UTF-8" ?><xml><records><record><database name="Cellulitis response search RCTs.enl" path="C:\Users\Conno\Downloads\Cellulitis response search RCTs.enl">Cellulitis response search RCTs.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>605</rec-number><foreign-keys><key app="EN" db-id="v99pw0vtkz9rrlevf57xs9tlx05r25wfrpzz">605</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Abrahamian, F. M.</style></author><author><style face="normal" font="default" size="100%">Sakoulas, G.</style></author><author><style face="normal" font="default" size="100%">Tzanis, E.</style></author><author><style face="normal" font="default" size="100%">Manley, A.</style></author><author><style face="normal" font="default" size="100%">Steenbergen, J.</style></author><author><style face="normal" font="default" size="100%">Das, A. F.</style></author><author><style face="normal" font="default" size="100%">Eckburg, P. B.</style></author><author><style face="normal" font="default" size="100%">McGovern, P. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Emergency Medicine, Olive View-UCLA Medical Center, Sylmar.&#xD;David Geffen School of Medicine at University of California Los Angeles.&#xD;Division of Host-Microbe Systems and Therapeutics, Center for Immunity, Infection and Inflammation, University of California San Diego School of Medicine, La Jolla.&#xD;Paratek Pharmaceuticals, Inc., King of Prussia, Pennsylvania.&#xD;AD Stats Consulting, Guerneville, California.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Omadacycline for Acute Bacterial Skin and Skin Structure Infections</style></title><secondary-title><style face="normal" font="default" size="100%">Clin Infect Dis</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Clin Infect Dis</style></full-title></periodical><pages><style face="normal" font="default" size="100%">S23-s32</style></pages><volume><style face="normal" font="default" size="100%">69</style></volume><number><style face="normal" font="default" size="100%">Suppl 1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Acute Disease/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Administration, Intravenous</style></keyword><keyword><style face="normal" font="default" size="100%">Administration, Oral</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Aged, 80 and over</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Bacterial Agents/administration &amp; dosage/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Administration Routes</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Linezolid/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Methicillin-Resistant Staphylococcus aureus/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Skin/*drug effects/microbiology/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Skin Diseases, Bacterial/*drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Soft Tissue Infections/*drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Tetracyclines/administration &amp; dosage/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">*mrsa</style></keyword><keyword><style face="normal" font="default" size="100%">*acute bacterial skin and skin structure infections</style></keyword><keyword><style face="normal" font="default" size="100%">*omadacycline</style></keyword><keyword><style face="normal" font="default" size="100%">*skin infection</style></keyword><keyword><style face="normal" font="default" size="100%">*tetracyclines</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2019</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug 1</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1058-4838 (Print)&#xD;1058-4838</style></isbn><abstract><style face="normal" font="default" size="100%">BACKGROUND: Within the last decade, methicillin-resistant Staphylococcus aureus (MRSA) has emerged as a frequent cause of purulent skin and soft tissue infections. New therapeutic options are being investigated for these infections. METHODS: We report an integrated analysis of 2 randomized, controlled studies involving omadacycline, a novel aminomethylcycline, and linezolid for the treatment of acute bacterial skin and skin structure infections (ABSSSI). Omadacycline in Acute Skin and Skin Structure Infections Study 1 (OASIS-1) initiated patients on intravenous omadacycline or linezolid, with the option to transition to an oral formulation after day 3. OASIS-2 was an oral-only study of omadacycline versus linezolid. RESULTS: In total, 691 patients received omadacycline and 689 patients received linezolid. Infection types included wound infection in 46.8% of patients, cellulitis/erysipelas in 30.5%, and major abscess in 22.7%. Pathogens were identified in 73.2% of patients. S. aureus was detected in 74.7% and MRSA in 32.4% of patients in whom a pathogen was identified. Omadacycline was noninferior to linezolid using the Food and Drug Administration primary endpoint of early clinical response (86.2% vs 83.9%; difference 2.3, 95% confidence interval -1.5 to 6.2) and using the European Medicines Agency primary endpoint of investigator-assessed clinical response at the posttreatment evaluation. Clinical responses were similar across different infection types and infections caused by different pathogens. Treatment-emergent adverse events, mostly described as mild or moderate, were reported by 51.1% of patients receiving omadacycline and 41.2% of those receiving linezolid. CONCLUSIONS: Omadacycline was effective and safe in ABSSSI. CLINICAL TRIALS REGISTRATION: NCT02378480 and NCT02877927.</style></abstract><label><style face="normal" font="default" size="100%">Included by both</style></label><notes><style face="normal" font="default" size="100%">1537-6591&#xD;Abrahamian, Fredrick M&#xD;Sakoulas, George&#xD;Tzanis, Evan&#xD;Manley, Amy&#xD;Steenbergen, Judith&#xD;Das, Anita F&#xD;Eckburg, Paul B&#xD;McGovern, Paul C&#xD;Clinical Trial, Phase III&#xD;Journal Article&#xD;Multicenter Study&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6669297/pdf/ciz396.pdf</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC6669297</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1093/cid/ciz396&#xD;10.1093/cid/ciz396.</style></electronic-resource-num><research-notes><style face="normal" font="default" size="100%">Not in the majority but potentially includable </style></research-notes></record><record><database name="Cellulitis response search RCTs.enl" path="C:\Users\Conno\Downloads\Cellulitis response search RCTs.enl">Cellulitis response search RCTs.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>606</rec-number><foreign-keys><key app="EN" db-id="v99pw0vtkz9rrlevf57xs9tlx05r25wfrpzz">606</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Brindle, R.</style></author><author><style face="normal" font="default" size="100%">Williams, O. M.</style></author><author><style face="normal" font="default" size="100%">Davies, P.</style></author><author><style face="normal" font="default" size="100%">Harris, T.</style></author><author><style face="normal" font="default" size="100%">Jarman, H.</style></author><author><style face="normal" font="default" size="100%">Hay, A. D.</style></author><author><style face="normal" font="default" size="100%">Featherstone, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Microbiology and Infectious Diseases, Bristol Royal Infirmary, Bristol, UK.&#xD;General Practice Support Unit, Bristol Royal Infirmary, Bristol, UK.&#xD;Department of Emergency Medicine, Royal London Hospital, London, UK.&#xD;Department of Emergency Medicine, St George&apos;s University Hospitals, London, UK.&#xD;Centre for Academic Primary Care, University of Bristol, Bristol, UK.&#xD;Acute Medicine Unit, Queen Alexandra Hospital, Portsmouth, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Adjunctive clindamycin for cellulitis: a clinical trial comparing flucloxacillin with or without clindamycin for the treatment of limb cellulitis</style></title><secondary-title><style face="normal" font="default" size="100%">BMJ Open</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">BMJ Open</style></full-title></periodical><pages><style face="normal" font="default" size="100%">e013260</style></pages><volume><style face="normal" font="default" size="100%">7</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Bacterial Agents/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Cellulitis/*drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Clindamycin/adverse effects/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Therapy, Combination</style></keyword><keyword><style face="normal" font="default" size="100%">Extremities/*pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Floxacillin/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">*cellulitis</style></keyword><keyword><style face="normal" font="default" size="100%">*clindamycin</style></keyword><keyword><style face="normal" font="default" size="100%">*diarrhoea</style></keyword><keyword><style face="normal" font="default" size="100%">*erysipelas</style></keyword><keyword><style face="normal" font="default" size="100%">*flucloxacillin</style></keyword><keyword><style face="normal" font="default" size="100%">*limb</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2017</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar 17</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">2044-6055</style></isbn><abstract><style face="normal" font="default" size="100%">OBJECTIVE: To compare flucloxacillin with clindamycin to flucloxacillin alone for the treatment of limb cellulitis. DESIGN: Parallel, double-blinded, randomised controlled trial. SETTING: Emergency department attendances and general practice referrals within 20 hospitals in England. INTERVENTIONS: Flucloxacillin, at a minimum of 500 mg 4 times per day for 5 days, with clindamycin 300 mg 4 times per day for 2 days given orally versus flucloxacillin given alone. MAIN OUTCOME MEASURES: The primary outcome was improvement at day 5. This was defined as being afebrile with either a reduction in affected skin surface temperature or a reduction in the circumference of the affected area. Secondary outcomes included resolution of systemic features, resolution of inflammatory markers, recovery of renal function, reduction in the affected area, decrease in pain, return to work or normal activities and the absence of increased side effects. RESULTS: 410 patients were included in the trial. No significant difference was seen in improvement at day 5 for flucloxacillin with clindamycin (136/156, 87%) versus flucloxacillin alone (140/172, 81%)-OR 1.55 (95% CI 0.81 to 3.01), p=0.174. There was a significant difference in the number of patients with diarrhoea at day 5 in the flucloxacillin with clindamycin allocation (34/160, 22%) versus flucloxacillin alone (16/176, 9%)-OR 2.7 (95% CI 1.41 to 5.07), p=0.002. There was no clinically significant difference in any secondary outcome measures. There was no significant difference in the number of patients stating that they had returned to normal activities at the day 30 interview in the flucloxacillin with clindamycin allocation (99/121, 82%) versus flucloxacillin alone (104/129, 81%)-adjusted OR 0.90 (95% CI 0.44 to 1.84). CONCLUSIONS: The addition of a short course of clindamycin to flucloxacillin early on in limb cellulitis does not improve outcome. The addition of clindamycin doubles the likelihood of diarrhoea within the first few days. TRIAL REGISTRATION NUMBER: NCT01876628, Results.</style></abstract><label><style face="normal" font="default" size="100%">Included by both</style></label><notes><style face="normal" font="default" size="100%">2044-6055&#xD;Brindle, Richard&#xD;Williams, O Martin&#xD;Davies, Paul&#xD;Harris, Tim&#xD;Jarman, Heather&#xD;Hay, Alastair D&#xD;Featherstone, Peter&#xD;NIHR-RP-02-12-012/Department of Health/United Kingdom&#xD;PB-PG-0212-27015/Department of Health/United Kingdom&#xD;Comparative Study&#xD;Journal Article&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5372109/pdf/bmjopen-2016-013260.pdf</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC5372109</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1136/bmjopen-2016-013260&#xD;10.1136/bmjopen-2016-013260.</style></electronic-resource-num></record><record><database name="Cellulitis response search RCTs.enl" path="C:\Users\Conno\Downloads\Cellulitis response search RCTs.enl">Cellulitis response search RCTs.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>607</rec-number><foreign-keys><key app="EN" db-id="v99pw0vtkz9rrlevf57xs9tlx05r25wfrpzz">607</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bucko, A. D.</style></author><author><style face="normal" font="default" size="100%">Hunt, B. J.</style></author><author><style face="normal" font="default" size="100%">Kidd, S. L.</style></author><author><style face="normal" font="default" size="100%">Hom, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Academic Dermatology Associates, Albuquerque, New Mexico 87106-5239, USA. eatschen@aol.com</style></auth-address><titles><title><style face="normal" font="default" size="100%">Randomized, double-blind, multicenter comparison of oral cefditoren 200 or 400 mg BID with either cefuroxime 250 mg BID or cefadroxil 500 mg BID for the treatment of uncomplicated skin and skin-structure infections</style></title><secondary-title><style face="normal" font="default" size="100%">Clin Ther</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Clin Ther</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1134-47</style></pages><volume><style face="normal" font="default" size="100%">24</style></volume><number><style face="normal" font="default" size="100%">7</style></number><keywords><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Aged, 80 and over</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Bacterial Agents/*administration &amp; dosage/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Cefadroxil/*administration &amp; dosage/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Cefuroxime/*administration &amp; dosage/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Cephalosporins/*administration &amp; dosage/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Administration Schedule</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Therapy, Combination/*administration &amp; dosage/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Skin Diseases, Infectious/*drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Soft Tissue Infections/*drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2002</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0149-2918 (Print)&#xD;0149-2918</style></isbn><abstract><style face="normal" font="default" size="100%">BACKGROUND: Uncomplicated skin and skin-structure infections are commonly observed in medical practice. Because these infections typically are confined to the superficial layers and seldom lead to the destruction of skin structures and resultant systemic dissemination, in general they can be treated with an oral antibiotic with potent microbiologic activity against gram-positive pathogens. OBJECTIVE: This paper compares the efficacy and tolerability of 3 beta-lactam antibiotics in patients with uncomplicated skin and skin-structure infections. METHODS: Two double-blind, multicenter, parallel-group studies were conducted, in which patients aged &gt; or = 12 years with uncomplicated skin and skin-structure infections were randomized to receive cefditoren 200 or 400 mg, cefuroxime 250 mg, or cefadroxil 500 mg, each BID for 10 days. Study 1 compared cefditoren with cefuroxime; Study 2 compared cefditoren with cefadroxil. Clinical and microbiologic responses were assessed at a posttreatment visit (within 48 hours of treatment completion) and test-of-cure visit (7-14 days after treatment completion). Patients were monitored closely throughout the study with the use of physical examinations, clinical laboratory tests, and assessment of adverse events. RESULTS: A total of 1,685 patients (855 males, 830 females; mean age, 41.1 years [range, 12-95 years]) were enrolled. Within both studies, the 3 treatment groups were similar at baseline based on demographic characteristics and types of infection. Cellulitis (26%), wound infection (25%), and simple abscess (15%) were the most common infections. Clinical cure rates at the test-of-cure visit were 85% (443/523) for cefditoren 200 mg, 83% (427/516) for cefditoren 400 mg, 88% (234/265) for cefuroxime, and 85% (211/248) for cefadroxil. At the test-of-cure visit, cefditoren 200 mg had eradicated significantly fewer of the causative pathogens isolated before treatment in microbiologically evaluable patients than did cefuroxime in Study 1 (P = 0.043) but significantly more of the pathogens than did cefadroxil in Study 2 (P = 0.018). Eradication rates for the most commonly isolated pathogens were generally similar in the 3 treatment groups in both studies, with the only significant difference favoring cefditoren 200 and 400 mg over cefadroxil for Peptostreptococcus species in Study 2 (P = 0.016 and P = 0.003, respectively). A minority of patients (&lt; or = 5% in any treatment group) discontinued study-drug treatment prematurely due to a treatment-related adverse event, with statistically higher rates for cefditoren 400 mg than for cefditoren 200 mg and the comparator cephalosporins (each P &lt; 0.05). All 3 cephalosporins were generally well tolerated. Most adverse events (&gt;93%) were categorized as mild to moderate, with the most common being diarrhea, nausea, and headache. CONCLUSION: In this population of patients with uncomplicated skin and skin-structure infections, including those due to Staphylococcus aureus or Streptococcus pyogenes, the clinical cure rate and tolerability of cefditoren were comparable to those of cefuroxime and cefadroxil.</style></abstract><label><style face="normal" font="default" size="100%">Included by both</style></label><notes><style face="normal" font="default" size="100%">Bucko, Alicia D&#xD;Hunt, Barbara J&#xD;Kidd, Sarah L&#xD;Hom, Richard&#xD;Clinical Trial&#xD;Comparative Study&#xD;Journal Article&#xD;Multicenter Study&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/s0149-2918(02)80024-8&#xD;10.1016/s0149-2918(02)80024-8.</style></electronic-resource-num></record><record><database name="Cellulitis response search RCTs.enl" path="C:\Users\Conno\Downloads\Cellulitis response search RCTs.enl">Cellulitis response search RCTs.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>608</rec-number><foreign-keys><key app="EN" db-id="v99pw0vtkz9rrlevf57xs9tlx05r25wfrpzz">608</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Davis, J. S.</style></author><author><style face="normal" font="default" size="100%">Mackrow, C.</style></author><author><style face="normal" font="default" size="100%">Binks, P.</style></author><author><style face="normal" font="default" size="100%">Fletcher, W.</style></author><author><style face="normal" font="default" size="100%">Dettwiller, P.</style></author><author><style face="normal" font="default" size="100%">Marshall, C.</style></author><author><style face="normal" font="default" size="100%">Day, J.</style></author><author><style face="normal" font="default" size="100%">Pratt, W.</style></author><author><style face="normal" font="default" size="100%">Tong, S. Y.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Global and Tropical Health Division, Menzies School of Health Research and Charles Darwin University, Darwin, Northern Territory, Australia; Department of Infectious Diseases, John Hunter Hospital and the University of Newcastle, Newcastle, New South Wales, Australia. Electronic address: Joshua.Davis@menzies.edu.au.&#xD;Hospital in the Home Program, Royal Darwin Hospital, Darwin, Northern Territory, Australia.&#xD;Global and Tropical Health Division, Menzies School of Health Research and Charles Darwin University, Darwin, Northern Territory, Australia.&#xD;Katherine Rural Clinical School, Flinders University, Katherine, Northern Territory, Australia.&#xD;Hospital in the Home Program, Shoalhaven Hospital, Nowra, New South Wales, Australia.&#xD;Global and Tropical Health Division, Menzies School of Health Research and Charles Darwin University, Darwin, Northern Territory, Australia; Victorian Infectious Diseases Service, The Royal Melbourne Hospital, and the University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">A double-blind randomized controlled trial of ibuprofen compared to placebo for uncomplicated cellulitis of the upper or lower limb</style></title><secondary-title><style face="normal" font="default" size="100%">Clin Microbiol Infect</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Clin Microbiol Infect</style></full-title></periodical><pages><style face="normal" font="default" size="100%">242-246</style></pages><volume><style face="normal" font="default" size="100%">23</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Anti-Bacterial Agents/administration &amp; dosage/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">Cellulitis/diagnosis/*drug therapy/*pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Comorbidity</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Therapy, Combination</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Ibuprofen/administration &amp; dosage/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Lower Extremity/*pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Upper Extremity/*pathology</style></keyword><keyword><style face="normal" font="default" size="100%">*Cellulitis</style></keyword><keyword><style face="normal" font="default" size="100%">*Ibuprofen</style></keyword><keyword><style face="normal" font="default" size="100%">*Randomized</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2017</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1198-743x</style></isbn><abstract><style face="normal" font="default" size="100%">OBJECTIVES: Cellulitis is a common skin infection resulting in inflammation that may take weeks to resolve despite appropriate antibiotics. It is unclear whether the adjunctive use of nonsteroidal anti-inflammatory drugs hastens the resolution of inflammation in patients with cellulitis. METHODS: We conducted a double-blind, randomized controlled trial comparing ibuprofen 400 mg three times daily for 5 days with identical placebo in adults with uncomplicated cellulitis of the upper or lower limb who were treated with intravenous cefazolin via an outpatient parenteral antibiotic treatment service at one of two Australian hospitals. Participants were assessed twice daily by a study nurse. The primary outcome measure was the proportion of patients with regression of inflammation 48 hours after the first effective dose of parenteral antibiotics (trial registration ANZCTR 12611000515998). RESULTS: Fifty-one patients were enrolled; 48 had sufficient data available to be included in the modified intention-to-treat analysis. Inflammation had begun to regress at 48 hours in 20 participants (80%) in the ibuprofen group compared to 15 (65%) in the placebo group (absolute risk difference +15%; 95% confidence interval -10 to +40; p &gt;0.05). There was no significant difference in any secondary outcome. Ibuprofen appeared safe, with no patients developing renal impairment or necrotizing fasciitis. CONCLUSIONS: This trial demonstrated no significant benefit of adjunctive ibuprofen in adults with uncomplicated cellulitis. The trial was powered to detect a large effect, and hence it is unclear whether the 15% absolute increase in the primary end point in the ibuprofen group was attributable to chance.</style></abstract><label><style face="normal" font="default" size="100%">Included by both</style></label><notes><style face="normal" font="default" size="100%">1469-0691&#xD;Davis, J S&#xD;Mackrow, C&#xD;Binks, P&#xD;Fletcher, W&#xD;Dettwiller, P&#xD;Marshall, C&#xD;Day, J&#xD;Pratt, W&#xD;Tong, S Y C&#xD;Clinical Trial&#xD;Journal Article&#xD;Randomized Controlled Trial&#xD;England</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.cmi.2017.02.036&#xD;10.1016/j.cmi.2017.02.036. Epub 2017 Mar 6.</style></electronic-resource-num></record><record><database name="Cellulitis response search RCTs.enl" path="C:\Users\Conno\Downloads\Cellulitis response search RCTs.enl">Cellulitis response search RCTs.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>609</rec-number><foreign-keys><key app="EN" db-id="v99pw0vtkz9rrlevf57xs9tlx05r25wfrpzz">609</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Eron, L. J.</style></author><author><style face="normal" font="default" size="100%">King, P.</style></author><author><style face="normal" font="default" size="100%">Marineau, M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Antibiotic selection and hospital discharge of patients with cellulitis</style></title><secondary-title><style face="normal" font="default" size="100%">Infections in medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Infections in medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">381‐</style></pages><volume><style face="normal" font="default" size="100%">21</style></volume><number><style face="normal" font="default" size="100%">8</style></number><keywords><keyword><style face="normal" font="default" size="100%">*cellulitis /disease management /drug resistance /drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Article</style></keyword><keyword><style face="normal" font="default" size="100%">Clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">Controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">Cost effectiveness analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Disease severity</style></keyword><keyword><style face="normal" font="default" size="100%">Drug choice</style></keyword><keyword><style face="normal" font="default" size="100%">Drug cost</style></keyword><keyword><style face="normal" font="default" size="100%">Drug self administration</style></keyword><keyword><style face="normal" font="default" size="100%">Erythema /disease management /drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Fever /disease management /drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Hospital discharge</style></keyword><keyword><style face="normal" font="default" size="100%">Human</style></keyword><keyword><style face="normal" font="default" size="100%">Leukocytosis /disease management /drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Nonhuman</style></keyword><keyword><style face="normal" font="default" size="100%">Patient attitude</style></keyword><keyword><style face="normal" font="default" size="100%">Patient education</style></keyword><keyword><style face="normal" font="default" size="100%">Prescription</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective study</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized controlled trial</style></keyword><keyword><style face="normal" font="default" size="100%">Side effect /side effect</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment failure</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2004</style></year></dates><abstract><style face="normal" font="default" size="100%">Patients presenting to the hospital with moderate to severe cellulitis were randomized to receive either provider‐administered ceftriaxone or self‐administered cefazolin to determine the ease with which each regimen facilitated discharge from the hospital and the relative cost‐effectiveness of the 2 medications in this setting. Patients who receivéd ceftriaxone returned to the hospital daily for administration of their medication. Since cefazolin requainres twice‐ or thrice‐daily administration, an attempt was made to teach patients to self‐administer this drug before discharge. Because of refusal to self‐medicate or problems in learning the dosing procedure, it was more difficult to discharge patients for whom cefazolin was prescribed. There were no significant differences between the groups with regard to the rate of resolution of erythema, fever, and leukocytosis and the rate of cure. The higher cost of ceftriaxone was offset by its benefit in allowing immediate discharge from the hospital.</style></abstract><label><style face="normal" font="default" size="100%">Included by both</style></label><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00516484/full</style></url></related-urls></urls></record><record><database name="Cellulitis response search RCTs.enl" path="C:\Users\Conno\Downloads\Cellulitis response search RCTs.enl">Cellulitis response search RCTs.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>610</rec-number><foreign-keys><key app="EN" db-id="v99pw0vtkz9rrlevf57xs9tlx05r25wfrpzz">610</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Friedland, H. D.</style></author><author><style face="normal" font="default" size="100%">O&apos;Neal, T.</style></author><author><style face="normal" font="default" size="100%">Biek, D.</style></author><author><style face="normal" font="default" size="100%">Eckburg, P. B.</style></author><author><style face="normal" font="default" size="100%">Rank, D. R.</style></author><author><style face="normal" font="default" size="100%">Llorens, L.</style></author><author><style face="normal" font="default" size="100%">Smith, A.</style></author><author><style face="normal" font="default" size="100%">Witherell, G. W.</style></author><author><style face="normal" font="default" size="100%">Laudano, J. B.</style></author><author><style face="normal" font="default" size="100%">Thye, D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Cerexa, Inc, Oakland, California, USA. dfriedland@cerexa.com</style></auth-address><titles><title><style face="normal" font="default" size="100%">CANVAS 1 and 2: analysis of clinical response at day 3 in two phase 3 trials of ceftaroline fosamil versus vancomycin plus aztreonam in treatment of acute bacterial skin and skin structure infections</style></title><secondary-title><style face="normal" font="default" size="100%">Antimicrob Agents Chemother</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Antimicrob Agents Chemother</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2231-6</style></pages><volume><style face="normal" font="default" size="100%">56</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">Acute Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Aged, 80 and over</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Bacterial Agents/administration &amp; dosage/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Aztreonam/administration &amp; dosage/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers/*analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Cephalosporins/administration &amp; dosage/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Administration Schedule</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Gram-Negative Bacteria/drug effects/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Gram-Positive Bacteria/drug effects/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Injections, Intravenous</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Methicillin-Resistant Staphylococcus aureus/drug effects/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Retrospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Skin Diseases, Bacterial/*drug therapy/microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Vancomycin/administration &amp; dosage/*therapeutic use</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0066-4804 (Print)&#xD;0066-4804</style></isbn><abstract><style face="normal" font="default" size="100%">Scientific and regulatory interest in assessing clinical endpoints after 48 to 72 h of treatment for acute bacterial skin and skin structure infections (ABSSSI) has increased. Historical, pre-antibiotic-era data suggest that a treatment effect relative to untreated controls can be discerned in this time interval. Ceftaroline fosamil, a broad-spectrum bactericidal cephalosporin with activity against Gram-positive organisms, including methicillin-resistant Staphylococcus aureus (MRSA), and Gram-negative organisms was efficacious in two phase 3 trials of complicated skin infections (CANVAS 1 and 2) using clinical cure rates at the test-of-cure visit. To assess an early clinical response in the CANVAS trials, a retrospective analysis using a day 3 clinical endpoint was conducted. Adults with ABSSSI received intravenous ceftaroline fosamil at 600 mg every 12 h (q12h) or vancomycin at 1 g plus aztreonam at 1 g (V/A) q12h for 5 to 14 days. Clinical response at day 3, defined as cessation of infection spread and absence of fever, was analyzed in patients with a lesion size of ≥ 75 cm(2) and either deep and/or extensive cellulitis, major abscess, or an infected wound. Day 3 integrated CANVAS clinical response rates were 74.0% (296/400) for ceftaroline and 66.2% (263/397) for V/A (difference, 7.8%; 95% confidence interval [CI], 1.3% to 14.0%). In the individual studies, absolute treatment differences of 9.4% (CANVAS 1) and 5.9% (CANVAS 2) favoring ceftaroline were observed. For ABSSSI due to MRSA, response rates were 81.7% and 77.4% in the ceftaroline and V/A groups, respectively. In this retrospective analysis, ceftaroline fosamil monotherapy had a numerically higher clinical response than V/A at day 3 in the treatment of ABSSSI.</style></abstract><label><style face="normal" font="default" size="100%">Included by Charlotte</style></label><notes><style face="normal" font="default" size="100%">1098-6596&#xD;Friedland, H David&#xD;O&apos;Neal, Tanya&#xD;Biek, Donald&#xD;Eckburg, Paul B&#xD;Rank, Douglas R&#xD;Llorens, Lily&#xD;Smith, Alex&#xD;Witherell, Gary W&#xD;Laudano, Joseph B&#xD;Thye, Dirk&#xD;Clinical Trial, Phase III&#xD;Journal Article&#xD;Multicenter Study&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3346585/pdf/zac2231.pdf</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC3346585</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1128/aac.05738-11&#xD;10.1128/AAC.05738-11. Epub 2012 Feb 6.</style></electronic-resource-num></record><record><database name="Cellulitis response search RCTs.enl" path="C:\Users\Conno\Downloads\Cellulitis response search RCTs.enl">Cellulitis response search RCTs.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>611</rec-number><foreign-keys><key app="EN" db-id="v99pw0vtkz9rrlevf57xs9tlx05r25wfrpzz">611</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Giordano, P. A.</style></author><author><style face="normal" font="default" size="100%">Pogue, J. M.</style></author><author><style face="normal" font="default" size="100%">Cammarata, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Emergency Medicine, Orlando Health, Florida.&#xD;Division of Infectious Diseases, Detroit Medical Center, Wayne State University, Michigan.&#xD;Melinta Therapeutics, Lincolnshire, Illinois.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Analysis of Pooled Phase III Efficacy Data for Delafloxacin in Acute Bacterial Skin and Skin Structure Infections</style></title><secondary-title><style face="normal" font="default" size="100%">Clin Infect Dis</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Clin Infect Dis</style></full-title></periodical><pages><style face="normal" font="default" size="100%">S223-s232</style></pages><volume><style face="normal" font="default" size="100%">68</style></volume><number><style face="normal" font="default" size="100%">Suppl 3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Administration, Intravenous</style></keyword><keyword><style face="normal" font="default" size="100%">Administration, Oral</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Aged, 80 and over</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Bacterial Agents/*pharmacology/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Therapy, Combination</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Fluoroquinolones/*pharmacology/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Skin Diseases, Bacterial/*drug therapy/*microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">Soft Tissue Infections/*drug therapy/*microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">*absssi</style></keyword><keyword><style face="normal" font="default" size="100%">*delafloxacin</style></keyword><keyword><style face="normal" font="default" size="100%">*fluoroquinolone</style></keyword><keyword><style face="normal" font="default" size="100%">*skin</style></keyword><keyword><style face="normal" font="default" size="100%">*vancomycin</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2019</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr 8</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1058-4838 (Print)&#xD;1058-4838</style></isbn><abstract><style face="normal" font="default" size="100%">BACKGROUND: Delafloxacin is an oral or intravenous (IV) antibiotic indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI), including both gram-positive (including methicillin-resistant Staphylococcus aureus [MRSA]) and gram-negative organisms. Chemically distinct from other quinolones, delafloxacin exhibits enhanced potency, particularly against gram-positive pathogens. The integration of efficacy data across the Phase III ABSSSI studies is presented here and allows for additional examination of results across subgroups. METHODS: Results of 2 multicenter, randomized, double-blind trials of 1510 adults with ABSSSI were pooled for this analysis. Subjects in the vancomycin arm received 15 mg/kg, plus 1-2 g of aztreonam every 12 hours. Delafloxacin was dosed at 300 mg IV every 12 hours in Study 302; dosing in Study 303 was 300 mg IV every 12 hours for 3 days, with a mandatory, blinded switch to delafloxacin at 450 mg orally every 12 hours. The primary endpoint was objective response (OR), defined as a ≥20% reduction of lesion spread of erythema area at the primary infection site at 48 to 72 hours (±2 hours), in the absence of clinical failure. Investigator-assessed response, based on the resolution of signs and symptoms at follow-up (FU; Day 14 ± 1) and late follow-up (LFU; Day 21- 28), were secondary endpoints. RESULTS: In the intent-to-treat analysis set, the OR was 81.3% in the delafloxacin arm and 80.7% in the comparator arm (mean treatment difference 0.8%, 95% confidence interval -3.2% to 4.7). Results for OR in the defined subgroups showed delafloxacin to be comparable to vancomycin/aztreonam. Investigator-assessed success was similar at FU (84.7% versus 84.1%) and LFU (82.0% versus 81.7%). Delafloxacin was comparable to vancomycin/aztreonam in the eradication of MRSA, at 98.1% versus 98.0%, respectively, at FU. The frequencies of treatment-emergent adverse events between the groups were similar. CONCLUSIONS: Overall, IV/oral delafloxacin fixed-dose monotherapy was non-inferior to IV vancomycin/aztreonam combination therapy and was well tolerated in each Phase III study, as well as in the pooled analysis, regardless of endpoint or analysis population.</style></abstract><label><style face="normal" font="default" size="100%">Included by both</style></label><notes><style face="normal" font="default" size="100%">1537-6591&#xD;Giordano, Philip A&#xD;Pogue, Jason M&#xD;Cammarata, Sue&#xD;Clinical Trial, Phase III&#xD;Journal Article&#xD;Multicenter Study&#xD;Randomized Controlled Trial</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6452004/pdf/ciz006.pdf</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC6452004</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1093/cid/ciz006&#xD;10.1093/cid/ciz006.</style></electronic-resource-num></record><record><database name="Cellulitis response search RCTs.enl" path="C:\Users\Conno\Downloads\Cellulitis response search RCTs.enl">Cellulitis response search RCTs.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>612</rec-number><foreign-keys><key app="EN" db-id="v99pw0vtkz9rrlevf57xs9tlx05r25wfrpzz">612</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Giordano, P. A.</style></author><author><style face="normal" font="default" size="100%">Rodriguez, M.</style></author><author><style face="normal" font="default" size="100%">Chitra, S.</style></author><author><style face="normal" font="default" size="100%">Manley, A.</style></author><author><style face="normal" font="default" size="100%">Volturo, G.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">126 Efficacy of Omadacycline in the Treatment of Acute Bacterial Skin and Skin Structure Infections in Patients With Cellulitis or Abscesses</style></title><secondary-title><style face="normal" font="default" size="100%">Annals of emergency medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Annals of Emergency Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">S49‐S50</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">*abscess</style></keyword><keyword><style face="normal" font="default" size="100%">*cellulitis</style></keyword><keyword><style face="normal" font="default" size="100%">*skin structure</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">Conference abstract</style></keyword><keyword><style face="normal" font="default" size="100%">Controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">Drug safety</style></keyword><keyword><style face="normal" font="default" size="100%">Drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Erysipelas</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Fever</style></keyword><keyword><style face="normal" font="default" size="100%">Hospital patient</style></keyword><keyword><style face="normal" font="default" size="100%">Human</style></keyword><keyword><style face="normal" font="default" size="100%">Infectious agent</style></keyword><keyword><style face="normal" font="default" size="100%">Injection drug user</style></keyword><keyword><style face="normal" font="default" size="100%">Leukocyte count</style></keyword><keyword><style face="normal" font="default" size="100%">Major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Nausea and vomiting</style></keyword><keyword><style face="normal" font="default" size="100%">Nonhuman</style></keyword><keyword><style face="normal" font="default" size="100%">Outpatient</style></keyword><keyword><style face="normal" font="default" size="100%">Post hoc analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized controlled trial</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment duration</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2020</style></year></dates><abstract><style face="normal" font="default" size="100%">Study Objectives: Patients with acute bacterial skin and skin structure infections (ABSSSI) are often admitted for intravenous (IV) antibiotic administration. Omadacycline (OMC) is a novel aminomethylcycline antibiotic, approved for community‐acquired bacterial pneumonia and ABSSSI, with activity against key causative pathogens, notably methicillin‐susceptible (MSSA) and resistant (MRSA) Staphylococcus aureus. We report pooled results from a post‐hoc analysis in patients with cellulitis/erysipelas or major abscesses who were not people who inject drugs (PWID), from the Omadacycline in Acute Skin and Skin Structure Infections (OASIS)‐1 and ‐2 studies. Methods: Patients with ABSSSI were randomized to OMC or linezolid (LZD), both IV‐to‐oral, in OASIS‐1 (NCT02378480); and to once‐daily oral OMC or twice‐daily oral LZD in OASIS‐2 (NCT02877927). Total therapy duration was 7‐14 days. Populations included modified intent‐to‐treat (mITT, randomized patients without a sole Gram‐negative pathogen); and micro‐mITT (mITT patients with ≥1 identified Gram‐positive causative pathogen). Primary endpoint: early clinical response (ECR) in the mITT population (survival with ≥20% reduction in lesion size, 48‐72 h after first dose, without rescue therapy). Secondary endpoint: survival with infection resolution/improvement at post‐treatment evaluation in the mITT population (PTE; 7‐14 days after last dose). Results: Baseline characteristics were generally similar between groups. In the mITT population, 294 patients had cellulitis/erysipelas (148 OMC, 146 LZD); 146 patients had major abscesses (77 OMC, 69 LZD). In the micro‐mITT population, S. aureus was the primary baseline pathogen, detected in 111 (76%) of patients with cellulitis/erysipelas and in 94 (76%) of patients with major abscesses (Table). MRSA was detected in 46 (41%) patients with cellulitis/erysipelas and in 56 (60%) patients with major abscesses. ECR was achieved in 117 (79%) patients receiving OMC and 115 (79%) receiving LZD with cellulitis/erysipelas, and in 70 (91%) patients receiving OMC and 61 (88%) receiving LZD with major abscesses; these results were similar for patients who presented at baseline with low/high white blood cell counts, fever, and lesion sizes ≤300 cm2 (Table). Success at PTE was comparable between OMC and LZD across groups. When analyzed by baseline pathogen, high clinical success at PTE was observed with both OMC and LZD in patients with S. aureus for both infection types (cellulitis/erysipelas and major abscesses; Table). There were no new safety signals; nausea and vomiting were the most frequent treatment‐emergent adverse events across groups. Conclusion: OMC is a once‐daily, IV or oral option for inpatient and outpatient treatment of ABSSSI in patients with cellulitis or major abscesses, including those due to MRSA. [Formula presented]</style></abstract><label><style face="normal" font="default" size="100%">Included by Charlotte</style></label><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02202907/full</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.annemergmed.2020.09.137</style></electronic-resource-num></record><record><database name="Cellulitis response search RCTs.enl" path="C:\Users\Conno\Downloads\Cellulitis response search RCTs.enl">Cellulitis response search RCTs.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>613</rec-number><foreign-keys><key app="EN" db-id="v99pw0vtkz9rrlevf57xs9tlx05r25wfrpzz">613</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Huang, D. B.</style></author><author><style face="normal" font="default" size="100%">Corey, G. R.</style></author><author><style face="normal" font="default" size="100%">Holland, T. L.</style></author><author><style face="normal" font="default" size="100%">Lodise, T.</style></author><author><style face="normal" font="default" size="100%">O&apos;Riordan, W.</style></author><author><style face="normal" font="default" size="100%">Wilcox, M. H.</style></author><author><style face="normal" font="default" size="100%">File, T. M., Jr.</style></author><author><style face="normal" font="default" size="100%">Dryden, M.</style></author><author><style face="normal" font="default" size="100%">Balser, B.</style></author><author><style face="normal" font="default" size="100%">Desplats, E.</style></author><author><style face="normal" font="default" size="100%">Torres, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Motif BioSciences, New York, NY, USA, and Rutgers New Jersey Medical School, Trenton, NJ, USA. Electronic address: david.huang@motifbio.com.&#xD;Duke University Medical Center, Durham, NC, USA.&#xD;Albany College of Pharmacy and Health Sciences, Albany, NY, USA.&#xD;eStudySite, San Diego, CA, USA.&#xD;Leeds Teaching Hospitals &amp; University of Leeds, Leeds, UK.&#xD;Summa Health, Akron, OH, USA.&#xD;Department of Microbiology and Infection, Hampshire Hospitals NHS Foundation Trust, UK.&#xD;Veristat, Southborough, MA, USA.&#xD;Department of Pulmonology, Hospital Clinic of Barcelona, University of Barcelona, Institut d&apos;Investigacions Biomèdiques August Pi i Sunyer, Centro de Investigación Biomedica en red de Enfermedades Respiratorias, Barcelona, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Pooled analysis of the phase 3 REVIVE trials: randomised, double-blind studies to evaluate the safety and efficacy of iclaprim versus vancomycin for treatment of acute bacterial skin and skin-structure infections</style></title><secondary-title><style face="normal" font="default" size="100%">Int J Antimicrob Agents</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Int J Antimicrob Agents</style></full-title></periodical><pages><style face="normal" font="default" size="100%">233-240</style></pages><volume><style face="normal" font="default" size="100%">52</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Acute Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Bacterial Agents/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Creatinine/blood</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Administration Schedule</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Methicillin-Resistant Staphylococcus aureus/drug effects/growth &amp; development</style></keyword><keyword><style face="normal" font="default" size="100%">Microbial Sensitivity Tests</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Patient Safety</style></keyword><keyword><style face="normal" font="default" size="100%">Pyrimidines/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Skin Diseases, Bacterial/*drug therapy/microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">Staphylococcal Infections/*drug therapy/microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">Staphylococcus aureus/drug effects/growth &amp; development</style></keyword><keyword><style face="normal" font="default" size="100%">Streptococcal Infections/*drug therapy/microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">Streptococcus pyogenes/drug effects/growth &amp; development</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Vancomycin/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Acute bacterial skin and skin-structure infection</style></keyword><keyword><style face="normal" font="default" size="100%">Iclaprim</style></keyword><keyword><style face="normal" font="default" size="100%">Vancomycin</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2018</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0924-8579</style></isbn><abstract><style face="normal" font="default" size="100%">Iclaprim, a diaminopyrimidine antimicrobial, was compared with vancomycin for treatment of patients with acute bacterial skin and skin-structure infections (ABSSSIs) in two studies (REVIVE-1 and REVIVE-2). Here, the efficacy and tolerability of iclaprim in a pooled analysis of results from both studies was explored. REVIVE-1 and REVIVE-2 were phase 3, double-blind, randomised, multicentre, active-controlled, non-inferiority (margin of 10%) trials, each designed to enrol 600 patients with ABSSSI using identical study protocols. Iclaprim 80 mg and vancomycin 15 mg/kg were administered intravenously every 12 h for 5-14 days. The primary endpoint was a ≥20% reduction from baseline in lesion size [early clinical response (ECR)] at the early time point (ETP) (48-72 h after starting study drug) in the intent-to-treat population. In REVIVE-1, ECR at the ETP was 80.9% with iclaprim versus 81.0% with vancomycin (treatment difference -0.13%, 95% CI -6.42% to 6.17%). In REVIVE-2, ECR was 78.3% with iclaprim versus 76.7% with vancomycin (treatment difference 1.58%, 95% CI -5.10% to 8.26%). The pooled ECR was 79.6% with iclaprim versus 78.8% with vancomycin (treatment difference 0.75%, 95% CI -3.84 to 5.35%). Iclaprim and vancomycin were comparable for the incidence of mostly mild adverse events, except for a higher incidence of elevated serum creatinine with vancomycin (n = 7) compared with iclaprim (n = 0). Iclaprim achieved non-inferiority compared with vancomycin for ECR at the ETP and secondary endpoints with a similar safety profile in two phase 3 studies for treatment of ABSSSI suspected or confirmed as caused by Gram-positive pathogens. [Clinical Trials Registration. NCT02600611 and NCT02607618.].</style></abstract><label><style face="normal" font="default" size="100%">Included by both</style></label><notes><style face="normal" font="default" size="100%">1872-7913&#xD;Huang, David B&#xD;Corey, G Ralph&#xD;Holland, Thomas L&#xD;Lodise, Thomas&#xD;O&apos;Riordan, William&#xD;Wilcox, Mark H&#xD;File, Thomas M Jr&#xD;Dryden, Matthew&#xD;Balser, Barbara&#xD;Desplats, Eve&#xD;Torres, Antoni&#xD;Clinical Trial, Phase III&#xD;Journal Article&#xD;Randomized Controlled Trial&#xD;Netherlands</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.ijantimicag.2018.05.012&#xD;10.1016/j.ijantimicag.2018.05.012. Epub 2018 May 19.</style></electronic-resource-num><research-notes><style face="normal" font="default" size="100%">Figure 4 may have some relevant info </style></research-notes></record><record><database name="Cellulitis response search RCTs.enl" path="C:\Users\Conno\Downloads\Cellulitis response search RCTs.enl">Cellulitis response search RCTs.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>614</rec-number><foreign-keys><key app="EN" db-id="v99pw0vtkz9rrlevf57xs9tlx05r25wfrpzz">614</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Huang, D. B.</style></author><author><style face="normal" font="default" size="100%">O&apos;Riordan, W.</style></author><author><style face="normal" font="default" size="100%">Overcash, J. S.</style></author><author><style face="normal" font="default" size="100%">Heller, B.</style></author><author><style face="normal" font="default" size="100%">Amin, F.</style></author><author><style face="normal" font="default" size="100%">File, T. M.</style></author><author><style face="normal" font="default" size="100%">Wilcox, M. H.</style></author><author><style face="normal" font="default" size="100%">Torres, A.</style></author><author><style face="normal" font="default" size="100%">Dryden, M.</style></author><author><style face="normal" font="default" size="100%">Holland, T. L.</style></author><author><style face="normal" font="default" size="100%">McLeroth, P.</style></author><author><style face="normal" font="default" size="100%">Shukla, R.</style></author><author><style face="normal" font="default" size="100%">Corey, G. R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Motif BioSciences, New York, New York.&#xD;eStudySites, San Diego, California.&#xD;Long Beach Clinical Trials, Long Beach, California.&#xD;Vohra Wound Physicians, Miramar, Florida.&#xD;Summa Health, Akron, Ohio.&#xD;Leeds Teaching Hospitals &amp; University of Leeds, Leeds, United Kingdom.&#xD;Department of Pulmonology, Hospital Clinic of Barcelona, University of Barcelona, Institut D&apos;investigacions August Pi I Sunyer, and Centro de Investigación Biomedica En Red-Enfermedades Respiratorias, Spain.&#xD;Department of Microbiology and Infection, Hampshire Hospitals NHS Foundation Trust, United Kingdom.&#xD;Duke University Medical Center, Durham, North Carolina.&#xD;Covance, Princeton, New Jersey.</style></auth-address><titles><title><style face="normal" font="default" size="100%">A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Iclaprim Vs Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed to be Due to Gram-Positive Pathogens: REVIVE-1</style></title><secondary-title><style face="normal" font="default" size="100%">Clin Infect Dis</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Clin Infect Dis</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1222-1229</style></pages><volume><style face="normal" font="default" size="100%">66</style></volume><number><style face="normal" font="default" size="100%">8</style></number><keywords><keyword><style face="normal" font="default" size="100%">Administration, Intravenous</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Bacterial Agents/administration &amp; dosage/*pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Gram-Positive Bacteria/*drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Gram-Positive Bacterial Infections/*drug therapy/microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Pyrimidines/administration &amp; dosage/*pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Skin/microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">Skin Diseases, Bacterial/*drug therapy/microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Vancomycin/administration &amp; dosage/*pharmacology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2018</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr 3</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1058-4838</style></isbn><abstract><style face="normal" font="default" size="100%">BACKGROUND: Our objective in this study was to demonstrate the safety and efficacy of iclaprim compared with vancomycin for the treatment of patients with acute bacterial skin and skin structure infections (ABSSSIs). METHODS: REVIVE-1 was a phase 3, 600-patient, double-blinded, randomized (1:1), active-controlled trial among patients with ABSSSI that compared the safety and efficacy of iclaprim 80 mg fixed dose with vancomycin 15 mg/kg, both administered intravenously every 12 hours for 5-14 days. The primary endpoint of this study was a ≥20% reduction in lesion size (early clinical response [ECR]) compared with baseline among patients randomized to iclaprim or vancomycin at the early time point (ETP), 48 to 72 hours after the start of administration of study drug in the intent-to-treat population. RESULTS: ECR among patients who received iclaprim and vancomycin at the ETP was 80.9% (241 of 298) of patients receiving iclaprim compared with 81.0% (243 of 300) of those receiving vancomycin (treatment difference, -0.13%; 95% confidence interval, -6.42%-6.17%). Iclaprim was well tolerated in the study, with most adverse events categorized as mild. CONCLUSIONS: Iclaprim achieved noninferiority (10% margin) at ETP compared with vancomycin and was well tolerated in this phase 3 clinical trial for the treatment of ABSSSI. Based on these results, iclaprim appears to be an efficacious and safe treatment for ABSSSI suspected or confirmed to be due to gram-positive pathogens. CLINICAL TRIALS REGISTRATION: NCT02600611.</style></abstract><label><style face="normal" font="default" size="100%">Included by Charlotte</style></label><notes><style face="normal" font="default" size="100%">1537-6591&#xD;Huang, David B&#xD;O&apos;Riordan, William&#xD;Overcash, J Scott&#xD;Heller, Barry&#xD;Amin, Faisal&#xD;File, Thomas M&#xD;Wilcox, Mark H&#xD;Torres, Antoni&#xD;Dryden, Matthew&#xD;Holland, Thomas L&#xD;McLeroth, Patrick&#xD;Shukla, Rajesh&#xD;Corey, G Ralph&#xD;Clinical Trial, Phase III&#xD;Journal Article&#xD;Multicenter Study&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://watermark.silverchair.com/cix987.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAqgwggKkBgkqhkiG9w0BBwagggKVMIICkQIBADCCAooGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMoH4CRmzU26CmKZl6AgEQgIICW3N_izYEGfPA5k4-YS34asrHuKT_OPrIyZcxcr5UoP2Ox-4GuSF2Tskn4mrEwFXgoBtMQnuwrm6bli2wq6Tt64xEDe202F_js6ziSn8D6Gvf0jZpaVOCLmV070psekiE1URC35G3zD58qlHkn_4sTWJpkRP4Mn4fnVuQsgtKMqHnGkinYPTokYaTOCch7FQAq21WmpJPjzOIuGVqJnLjiwQ51ayydOkKtzq6gCnLpM0QO4ZRQlr7PGcdO8f4xLTKGenWNLD0LVaaZEzJB17SFILIF_woSmSGM1acu4QPfzbFcgKsCQ6JuIpnIDoeuRwMHlXejVL0zbdvJdJleu0hu7Kk-xDkXlbjX4DPyTCZYdTdIHpmHmEY0a0igGS8FeooZRDT_7COAVeIYrFhxAW-echrb0YnVr3g9HKOGRvcIGyzY5jdfgLkChAMRBqaTNvZWMNVS0hCoCKDA-Mtts_orQeC-yRKDEBHIlHcydwHpeb2ViSKoov4L3tAHbicAgQ3qbGuzM9C-DiJLvcslSl2u2RBV674kdPrNy3Z0LnJmz5Kl9tFs6TJe2SeN4_xHGGb2RcxdjRZECLJXTcXa8xFqMj9AnNBJpS3E50se2lXnrZsARB7YUkxhlCodKCAAlmIuWk61uuTXs2iJ8EJDU59sQ9KGcViictw08xDBL2oV2ltnJQL2lnMD6GPE04WH8b6yAkzkuyW4LzKDg2POQXP93L3DaKw7PFoLxcYU_ujobOiOSavZ9p5I02f9h7XCYmmSJPwY--QS3M16OHGgSvsjJWnA_9EoBfJmA5Yew</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1093/cid/cix987&#xD;10.1093/cid/cix987.</style></electronic-resource-num><research-notes><style face="normal" font="default" size="100%">Cellulitis is not the majority </style></research-notes></record><record><database name="Cellulitis response search RCTs.enl" path="C:\Users\Conno\Downloads\Cellulitis response search RCTs.enl">Cellulitis response search RCTs.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>615</rec-number><foreign-keys><key app="EN" db-id="v99pw0vtkz9rrlevf57xs9tlx05r25wfrpzz">615</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ibrahim, L.</style></author><author><style face="normal" font="default" size="100%">Hopper, S.</style></author><author><style face="normal" font="default" size="100%">Orsini, F.</style></author><author><style face="normal" font="default" size="100%">Daley, A.</style></author><author><style face="normal" font="default" size="100%">Babl, F.</style></author><author><style face="normal" font="default" size="100%">Bryant, P.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Challenging the dogmas of outpatient parenteral antimicrobial terapy trough a randomized controlled trial</style></title><secondary-title><style face="normal" font="default" size="100%">Open forum infectious diseases</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Open Forum Infectious Diseases</style></full-title></periodical><pages><style face="normal" font="default" size="100%">S117‐</style></pages><volume><style face="normal" font="default" size="100%">5</style></volume><keywords><keyword><style face="normal" font="default" size="100%">*outpatient</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Antimicrobial therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Catheter</style></keyword><keyword><style face="normal" font="default" size="100%">Cellulitis</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Complication</style></keyword><keyword><style face="normal" font="default" size="100%">Conference abstract</style></keyword><keyword><style face="normal" font="default" size="100%">Controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">Drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Emergency ward</style></keyword><keyword><style face="normal" font="default" size="100%">Feces</style></keyword><keyword><style face="normal" font="default" size="100%">Hospital care</style></keyword><keyword><style face="normal" font="default" size="100%">Hospital readmission</style></keyword><keyword><style face="normal" font="default" size="100%">Hospitalization</style></keyword><keyword><style face="normal" font="default" size="100%">Human</style></keyword><keyword><style face="normal" font="default" size="100%">Major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Outcome assessment</style></keyword><keyword><style face="normal" font="default" size="100%">Pediatric hospital</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized controlled trial</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment failure</style></keyword><keyword><style face="normal" font="default" size="100%">Vein catheterization</style></keyword><keyword><style face="normal" font="default" size="100%">Young adult</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2018</style></year></dates><abstract><style face="normal" font="default" size="100%">Background. Outpatient parenteral antimicrobial therapy (OPAT) has shifed from being a novel concept to an accepted model of care for some conditions. However, concerns remain that have limited its broader roll out: the use of daily cefriaxone regarding its efficacy and impact on antibiotic resistance, intravenous (IV) catheter complications, risk of treating an acute infection directly from the emergency room (ER), and concern that OPAT has shifed the burden of cost from hospitals to patients. We aimed to address these questions with the first randomized controlled trial (RCT) of OPAT efficacy in children: comparing OPAT directly from the ER using IV cefriax‐one with hospitalization using IV fucloxacillin for moderate/severe cellulitis. Methods. The RCT was set at a tertiary pediatric hospital from January 2015 to June 2017. Inclusion criteria: children 6 months‐18 years with uncomplicated cellulitis needing IV antibiotics. Patients were randomized to cefriaxone via OPAT at home or fucloxacillin in hospital, using a peripheral catheter. Primary outcome: treatment failure within 48 hours due to lack of improvement or adverse events. Secondary outcomes: complications, readmission, acquisition of nasal and stool‐resistant bacteria and costs. Results. A total of 188 children were randomized: 93 to OPAT and 95 to hospital. In the intention‐to‐treat population, there was no diference in treatment failure between OPAT and hospital (2% vs. 7%, P = 0.09). Per protocol, OPAT had less failure (1% vs. 8%, P = 0.03). Tere was no increased acquisition of MRSA, ESBL, VRE or C. difcile with OPAT compared with in hospital at 1 week or 3 months (P &gt; 0.05). Complication rates were similar (6% vs. 7%, P = 0.78), and repeat IV catheterization was less with OPAT (3% vs. 15%, P = 0.002). Readmission was 1% on OPAT. The cost to families was signifcantly less with OPAT (AUD213 vs. AUD733, P &lt; 0.001). Conclusion. D espite t he ac uity of the infection, OPAT wit h IV cefriaxone for moderate/severe cellulitis in children is efcacious with complications and readmissions no diferent from hospital care with IV fucloxacillin. Short‐term cefriaxone use in healthy children on OPAT is not associated with increased acquisition of resistant organisms, and has reduced burden of costs to families.</style></abstract><label><style face="normal" font="default" size="100%">Included by both</style></label><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01995225/full</style></url><url><style face="normal" font="default" size="100%">https://watermark.silverchair.com/ofy210.296.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAr0wggK5BgkqhkiG9w0BBwagggKqMIICpgIBADCCAp8GCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMZd_icLR5r8os9x76AgEQgIICcH_235HiF5PciAcMcVPyxmxn-SpYKYe9l-_Se6c-0Uv81LZuuwKN4sxYr16sQcopg0QGNbsIvnCWPxvMSj4iX729Tu0HshTfzF7xV3psw5687myerT-6LXV-F_p8vUH9GH_IIuSfrsztGhM_k_Ezu5wa6MUpIA6LJoq33QO4n0dlFHLTjq0Dadiw4IkFscU9yFdojtkBzIDOP_pc-gaDlnCcKppwhjLd6kGnX7PF9JrAJ7qh7fNfFKj9rX36cZrjGrmzy0OPipkSOv5g0t_JURDVeBxln3sYmVQ-VHreWKGgDonAxPzxjk22mVUTNpkPf0VNHKBTEiWYaIeSa0dhavbsxQNwVFoFOjcyz865WrV9IQn5DZcIzKxcW6tnW8oNKekZCI0nBzPfWxKW5-7zqEhwfBOOzuwrzrHdmTciGlgi_kAH5czotiY96ZGI3zCIw0vANVFZQWy6wy_swg32P-PX0IGXz6k1_RPwtyWw9JDXcqALgiqTvrTl1k1OaXmtsPOma88rp-oZm-D1tBhvFIY16OKHibpEsj1SuG2paGHYtlH9iS7Fk78_9ExvjlumaiPLMoL7kKYEGlxTlzc-r6gnDGcOClGFbNnw_noJeJOSCyIzeedSTUXUUKsZoY1OyOLHTC69CF408ogu3v0XZMvvB269BPw2seRVOa6fMTGRbcQh9yUTdo7e55cUd0x-wHAaKdDQ2xzCtWcS_cF4ySM_qaCWDYHTkwCMwEKCQ2G93Filhd2FOa_CTE6M4wVhN0GdQYNNstOp8fhXdZJi54hnYoFhIcuZ1MUAGiayCqltf-SZOlM21xjPZpkdbL9RRg</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1093/ofid/ofy210.296</style></electronic-resource-num><research-notes><style face="normal" font="default" size="100%">Need to contact authors for full text?</style></research-notes></record><record><database name="Cellulitis response search RCTs.enl" path="C:\Users\Conno\Downloads\Cellulitis response search RCTs.enl">Cellulitis response search RCTs.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>616</rec-number><foreign-keys><key app="EN" db-id="v99pw0vtkz9rrlevf57xs9tlx05r25wfrpzz">616</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kingsley, J.</style></author><author><style face="normal" font="default" size="100%">Mehra, P.</style></author><author><style face="normal" font="default" size="100%">Lawrence, L. E.</style></author><author><style face="normal" font="default" size="100%">Henry, E.</style></author><author><style face="normal" font="default" size="100%">Duffy, E.</style></author><author><style face="normal" font="default" size="100%">Cammarata, S. K.</style></author><author><style face="normal" font="default" size="100%">Pullman, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Columbus Regional Research Institute, 800 Talbotton Road, Columbus, GA 31904, USA.&#xD;Artemis Institute for Clinical Research, 770 Washington St., San Diego, CA 92103, USA.&#xD;Melinta Therapeutics, 300 George Street, New Haven, CT 06511, USA.&#xD;H2O Clinical, 224 Schilling Circle, Hunt Valley, MD 21031, USA.&#xD;Melinta Therapeutics, 300 George Street, New Haven, CT 06511, USA scammarata@melinta.com.&#xD;Mercury Street Medical Group, PLLC, 300 West Mercury Street, Butte, MT 59701, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">A randomized, double-blind, Phase 2 study to evaluate subjective and objective outcomes in patients with acute bacterial skin and skin structure infections treated with delafloxacin, linezolid or vancomycin</style></title><secondary-title><style face="normal" font="default" size="100%">J Antimicrob Chemother</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Antimicrob Chemother</style></full-title></periodical><pages><style face="normal" font="default" size="100%">821-9</style></pages><volume><style face="normal" font="default" size="100%">71</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Administration, Intravenous</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Aged, 80 and over</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Bacterial Agents/adverse effects/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Fluoroquinolones/adverse effects/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Linezolid/adverse effects/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Skin Diseases, Bacterial/*drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Vancomycin/adverse effects/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0305-7453 (Print)&#xD;0305-7453</style></isbn><abstract><style face="normal" font="default" size="100%">OBJECTIVES: Delafloxacin is an investigational anionic fluoroquinolone being developed to treat infections caused by Gram-positive and -negative organisms. This clinical trial evaluated the efficacy and safety of delafloxacin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs). METHODS: In a double-blind, Phase 2 trial, 256 patients were randomized (1 : 1 : 1) to 300 mg of delafloxacin, 600 mg of linezolid or 15 mg/kg vancomycin (actual body weight), each administered intravenously twice daily for 5-14 days. Randomization was stratified by infection category. The primary endpoint was the investigator&apos;s assessment of cure, defined as complete resolution of baseline signs and symptoms at follow-up. Secondary endpoints included reductions in the total areas of erythema and induration and assessments of bacterial eradication. This trial has been registered at ClinicalTrials.gov under registration number NCT01283581. RESULTS: Cure rates were significantly greater with delafloxacin versus vancomycin (mean difference: -16.3%; 95% CI, -30.3% to -2.3%; P = 0.031); differences were significant for obese patients (BMI ≥30 kg/m(2); mean difference: -30.0%; 95% CI, -50.7% to -9.3%; P = 0.009), but not for non-obese patients. Cure rates with delafloxacin and linezolid were similar. Using digital measurement, the percentage decrease in total erythema area was significantly greater with delafloxacin versus vancomycin at follow-up (-96.4% versus -84.5%; P = 0.028). There were no differences in bacterial eradication among the treatment groups. The most frequently reported treatment-emergent adverse events were nausea, diarrhoea and vomiting. CONCLUSIONS: These data show that delafloxacin is effective in the treatment of ABSSSIs and is well tolerated.</style></abstract><label><style face="normal" font="default" size="100%">Included by both</style></label><notes><style face="normal" font="default" size="100%">1460-2091&#xD;Kingsley, Jeff&#xD;Mehra, Purvi&#xD;Lawrence, Laura E&#xD;Henry, Eugenia&#xD;Duffy, Erin&#xD;Cammarata, Sue K&#xD;Pullman, John&#xD;Clinical Trial, Phase II&#xD;Comparative Study&#xD;Journal Article&#xD;Multicenter Study&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4743703/pdf/dkv411.pdf</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC4743703</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1093/jac/dkv411&#xD;10.1093/jac/dkv411. Epub 2015 Dec 17.</style></electronic-resource-num></record><record><database name="Cellulitis response search RCTs.enl" path="C:\Users\Conno\Downloads\Cellulitis response search RCTs.enl">Cellulitis response search RCTs.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>617</rec-number><foreign-keys><key app="EN" db-id="v99pw0vtkz9rrlevf57xs9tlx05r25wfrpzz">617</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lipsky, B. A.</style></author><author><style face="normal" font="default" size="100%">Yarbrough Iii, D. R.</style></author><author><style face="normal" font="default" size="100%">Walker Iv, F. B.</style></author><author><style face="normal" font="default" size="100%">Powers, R. D.</style></author><author><style face="normal" font="default" size="100%">Morman, M. R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">B.A. Lipsky, General Internal Medicine Clinic, VA Medical Center, 1660 S. Columbian Way, Seattle, WA 98108, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Ofloxacin versus cephalexin for treating skin and soft tissue infections</style></title><secondary-title><style face="normal" font="default" size="100%">International Journal of Dermatology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">International Journal of Dermatology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">443-445</style></pages><volume><style face="normal" font="default" size="100%">31</style></volume><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">cefalexin</style></keyword><keyword><style face="normal" font="default" size="100%">ofloxacin</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">gastrointestinal symptom</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">neurotoxicity</style></keyword><keyword><style face="normal" font="default" size="100%">oral drug administration</style></keyword><keyword><style face="normal" font="default" size="100%">priority journal</style></keyword><keyword><style face="normal" font="default" size="100%">skin infection</style></keyword><keyword><style face="normal" font="default" size="100%">soft tissue infection</style></keyword><keyword><style face="normal" font="default" size="100%">floxin</style></keyword><keyword><style face="normal" font="default" size="100%">keflex</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1992</style></year></dates><isbn><style face="normal" font="default" size="100%">0011-9059</style></isbn><abstract><style face="normal" font="default" size="100%">Patients with acute localized skin or soft tissue infections were randomized to receive either ofloxacin (300 mg orally, b.i.d.) or cephalexin (500 mg orally, b.i.d.). Among 401 enrolled patients, 382 were evaluable for safety and 148 for microbiologic response. Microbiologic cure occurred in 93.4% of ofloxacin-treated patients and in 94.0% of those treated with cephalexin. Clinical cure or improvement, respectively, was found in 85.2% and 11.1% of patients treated with ofloxacin, and 83.6% and 14.9% of patients receiving cephalexin. Adverse effects (primarily associated with the gastrointestinal tract and central nervous system) were considered to be drug-related in 7.9% of those receiving ofloxacin and 4.8% of those receiving cephalexin. Thus, ofloxacin is as effective and well tolerated as cephalexin and a good alternate antibiotic for treating skin and skin structure infections caused by a variety of pathogens.</style></abstract><label><style face="normal" font="default" size="100%">Included by both</style></label><notes><style face="normal" font="default" size="100%">L22207030&#xD;1992-07-19</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L22207030&amp;from=export</style></url><url><style face="normal" font="default" size="100%">https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1365-4362.1992.tb02683.x?sid=nlm%3Apubmed</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">floxin&#xD;keflex</style></custom1></record><record><database name="Cellulitis response search RCTs.enl" path="C:\Users\Conno\Downloads\Cellulitis response search RCTs.enl">Cellulitis response search RCTs.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>618</rec-number><foreign-keys><key app="EN" db-id="v99pw0vtkz9rrlevf57xs9tlx05r25wfrpzz">618</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mills, J.</style></author><author><style face="normal" font="default" size="100%">Slutkin, G.</style></author><author><style face="normal" font="default" size="100%">Klein, D.</style></author><author><style face="normal" font="default" size="100%">Schecter, W.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Infect. Dis. Unit, Med. Serv., San Francisco Gen. Hosp.-Med. Cent., San Francisco, CA</style></auth-address><titles><title><style face="normal" font="default" size="100%">Ceftizoxime compared with cefamandole for treatment of soft tissue infections</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Antimicrobial Chemotherapy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Antimicrobial Chemotherapy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">273-279</style></pages><volume><style face="normal" font="default" size="100%">10</style></volume><number><style face="normal" font="default" size="100%">Suppl. C</style></number><keywords><keyword><style face="normal" font="default" size="100%">cefamandole</style></keyword><keyword><style face="normal" font="default" size="100%">ceftizoxime</style></keyword><keyword><style face="normal" font="default" size="100%">cellulitis</style></keyword><keyword><style face="normal" font="default" size="100%">clinical article</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">drug comparison</style></keyword><keyword><style face="normal" font="default" size="100%">drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial</style></keyword><keyword><style face="normal" font="default" size="100%">skin infection</style></keyword><keyword><style face="normal" font="default" size="100%">soft tissue</style></keyword><keyword><style face="normal" font="default" size="100%">soft tissue infection</style></keyword><keyword><style face="normal" font="default" size="100%">therapy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1982</style></year></dates><isbn><style face="normal" font="default" size="100%">0305-7453</style></isbn><abstract><style face="normal" font="default" size="100%">Acute skin and subcutaneous tissue infections in 64 adult patients were treated with ceftizoxime or cefamandole in a randomized study comparing the effectiveness of both drugs. Ceftizoxime (0.5-1.0 g twice daily) or cefamandole (0.5-1.0 g four times daily) was administered intravenously or intramuscularly for from 2 to longer than 7 days depending on response to treatment. Patients were evaluated clinically and bacteriologically for response to the drug and for drug safety. Both drugs provided effective antimicrobial therapy. Clinical response was good except in two elderly diabetic patients on cefamandole. Ceftizoxime at a dosage of 0.5-1.0 g twice daily proved to be as effective as cefamandole, 0.5-1.0 g administered four times daily. Both drugs were well tolerated; neither had to be discontinued because of adverse effects.</style></abstract><label><style face="normal" font="default" size="100%">Included by both</style></label><notes><style face="normal" font="default" size="100%">L13187820&#xD;1983-03-24</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L13187820&amp;from=export</style></url></related-urls></urls><research-notes><style face="normal" font="default" size="100%">Not sure when the responding time is for table 2</style></research-notes></record><record><database name="Cellulitis response search RCTs.enl" path="C:\Users\Conno\Downloads\Cellulitis response search RCTs.enl">Cellulitis response search RCTs.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>619</rec-number><foreign-keys><key app="EN" db-id="v99pw0vtkz9rrlevf57xs9tlx05r25wfrpzz">619</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Moran, G. J.</style></author><author><style face="normal" font="default" size="100%">Krishnadasan, A.</style></author><author><style face="normal" font="default" size="100%">Mower, W. R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">G.J. Moran</style></auth-address><titles><title><style face="normal" font="default" size="100%">Effect of cephalexin plus trimethoprim-sulfamethoxazole vs cephalexin alone on clinical cure of uncomplicated cellulitis</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Emergency Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Emergency Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">444</style></pages><volume><style face="normal" font="default" size="100%">53</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">cefalexin</style></keyword><keyword><style face="normal" font="default" size="100%">cotrimoxazole</style></keyword><keyword><style face="normal" font="default" size="100%">abscess</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">adverse event</style></keyword><keyword><style face="normal" font="default" size="100%">cellulitis</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">double blind procedure</style></keyword><keyword><style face="normal" font="default" size="100%">drug combination</style></keyword><keyword><style face="normal" font="default" size="100%">drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">echography</style></keyword><keyword><style face="normal" font="default" size="100%">emergency ward</style></keyword><keyword><style face="normal" font="default" size="100%">erythema</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">fever</style></keyword><keyword><style face="normal" font="default" size="100%">follow up</style></keyword><keyword><style face="normal" font="default" size="100%">hospital admission</style></keyword><keyword><style face="normal" font="default" size="100%">household</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">methicillin resistant Staphylococcus aureus</style></keyword><keyword><style face="normal" font="default" size="100%">multicenter study</style></keyword><keyword><style face="normal" font="default" size="100%">nonhuman</style></keyword><keyword><style face="normal" font="default" size="100%">outcome assessment</style></keyword><keyword><style face="normal" font="default" size="100%">chronic infection</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial</style></keyword><keyword><style face="normal" font="default" size="100%">skin infection</style></keyword><keyword><style face="normal" font="default" size="100%">soft tissue</style></keyword><keyword><style face="normal" font="default" size="100%">swelling</style></keyword><keyword><style face="normal" font="default" size="100%">treatment failure</style></keyword><keyword><style face="normal" font="default" size="100%">visually impaired person</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2017</style></year></dates><isbn><style face="normal" font="default" size="100%">0736-4679</style></isbn><abstract><style face="normal" font="default" size="100%">Current guidelines recommend treatment of uncomplicated cellulitis with an agent active only against betahemolytic streptococci. However, the prevalence of community-acquired methicillin-resistant Staphylococcus aureus (MRSA) is increasing, and it is unknown whether treating cellulitis with coverage against MRSA in addition to beta-hemolytic streptococci would lead to improved outcomes. This multicenter, double-blind, randomized trial compared a 7-day course of cephalexin plus trimethoprim-sulfamethoxazole (TMP-SMX) to a course of cephalexin alone in order to determine whether the addition of coverage against MRSA would lead to increased clinical cure rates in emergency department patients with uncomplicated cellulitis. The authors enrolled 500 patients over the age of 12 with a lesion measuring at least 2.0 centimeters in diameter for less than one week, and ruled out concurrent abscess with soft tissue ultrasonography in all patients prior to enrollment. Clinical cure was defined as absence of any criteria of treatment failure, which included signs of worsening infection (fever, increased erythema, worsened swelling or tenderness) at 3-4 day follow-up or persistent infection (erythema, swelling or tenderness) at 8-10 and 14-21 day follow-up. A clinically significant difference was defined as a greater than 10% difference in cure rates between the two groups. Clinical cure occurred at the final follow up visit in 83.5% of patients in the cephalexin plus TMP-SMX group and in 85.5% of patients in the cephalexin alone group (difference of 2.0%; 95% CI, 9.7% to 5.7%) in the per-protocol analysis, defined as those participants adherent to at least 75% of medication doses during the first five days and reachable in-person for the test-ofcure visit, or those with treatment failure despite at least 75% adherence. A modified intention-to-treat analysis which included all participants receiving at least one dose of medication and reachable by phone or in person for the test-of-cure visit showed clinical cure rates of 76.2% in the cephalexin plus TMPSMX and 69.0% in the cephalexin alone group (difference of 7.3%; 95% CI,-1.0% to 15.5%;). There was no difference in secondary outcomes between the two groups, defined as drainage procedures, hospital admissions, change in size of erythema, tenderness, or swelling, new skin infections, or infections in household contacts. The two study groups also had similar rates of adverse events, the majority of which were of mild in severity. The authors concluded that a regimen with activity against MRSA (cephalexin plus trimethoprim-sulfamethoxazole) was not superior to a regimen without MRSA coverage (cephalexin alone) in the treatment of non-purulent uncomplicated cellulitis Comment: This study shows that routine MRSA coverage has no added benefit over streptococcal coverage in uncomplicated cellulitis in the emergency department setting. However, the high rate of medication nonadherence or loss to follow up and the inclusion of the minimally important difference of 10% in the 95% confidence interval for the modified intention-to-treat analysis suggest further research may be warranted.</style></abstract><label><style face="normal" font="default" size="100%">Included by both</style></label><notes><style face="normal" font="default" size="100%">L618810055&#xD;2017-10-24</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L618810055&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1016/j.jemermed.2017.07.002</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.jemermed.2017.07.002</style></electronic-resource-num></record><record><database name="Cellulitis response search RCTs.enl" path="C:\Users\Conno\Downloads\Cellulitis response search RCTs.enl">Cellulitis response search RCTs.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>620</rec-number><foreign-keys><key app="EN" db-id="v99pw0vtkz9rrlevf57xs9tlx05r25wfrpzz">620</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Parish, L. C.</style></author><author><style face="normal" font="default" size="100%">Witkowski, J. A.</style></author><author><style face="normal" font="default" size="100%">Snow, R.</style></author><author><style face="normal" font="default" size="100%">Eron, L.</style></author><author><style face="normal" font="default" size="100%">Mogabgab, W. J.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Cephalosporins in cutaneous infections. A prospective comparison of two dosage regimens of ceftazidime for therapy of skin and skin structure infections</style></title><secondary-title><style face="normal" font="default" size="100%">Int J Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Int J Dermatol</style></full-title></periodical><pages><style face="normal" font="default" size="100%">258-65</style></pages><volume><style face="normal" font="default" size="100%">25</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Bacterial Infections/*drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Ceftazidime/*administration &amp; dosage/adverse effects/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Cellulitis/drug therapy/microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Administration Schedule</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Gram-Negative Bacteria/isolation &amp; purification</style></keyword><keyword><style face="normal" font="default" size="100%">Gram-Positive Bacteria/isolation &amp; purification</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Random Allocation</style></keyword><keyword><style face="normal" font="default" size="100%">Skin Diseases, Infectious/*drug therapy/microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">Skin Ulcer/drug therapy/microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">Wound Infection/drug therapy/microbiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1986</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0011-9059 (Print)&#xD;0011-9059</style></isbn><abstract><style face="normal" font="default" size="100%">The safety and efficacy of ceftazidime administered as 0.5 g every 8 hours (q8h) or 1.0 g q8h for at least 5 days were compared in 197 patients and found to be effective in the treatment of cellulitis, abscesses, skin ulcers, and wound infections. Staphylococcus aureus was the predominant pathogen in both treatment groups with approximately half of the isolates from each treatment group being gram-positive. Pseudomonas aeruginosa was the most common gram-negative isolate. P. aeruginosa, Proteus mirabilis, and Escherichia coli each comprised 5-12% of the isolates from each treatment group. Clinical cure or improvement was achieved in 98.7% of the patients in each treatment group. Concurrently with clinically successful treatment, a high rate of bacteriologic eradication without superinfection was achieved with the 0.5-g regimen (84% of all isolates) and the 1.0-g regimen (92%).</style></abstract><label><style face="normal" font="default" size="100%">Included by Charlotte</style></label><notes><style face="normal" font="default" size="100%">Parish, L C&#xD;Witkowski, J A&#xD;Snow, R&#xD;Eron, L&#xD;Mogabgab, W J&#xD;Clinical Trial&#xD;Comparative Study&#xD;Controlled Clinical Trial&#xD;Journal Article&#xD;Randomized Controlled Trial&#xD;England</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1365-4362.1986.tb02239.x?sid=nlm%3Apubmed</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/j.1365-4362.1986.tb02239.x&#xD;10.1111/j.1365-4362.1986.tb02239.x.</style></electronic-resource-num><research-notes><style face="normal" font="default" size="100%">Can we use figure 1?</style></research-notes></record><record><database name="Cellulitis response search RCTs.enl" path="C:\Users\Conno\Downloads\Cellulitis response search RCTs.enl">Cellulitis response search RCTs.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>621</rec-number><foreign-keys><key app="EN" db-id="v99pw0vtkz9rrlevf57xs9tlx05r25wfrpzz">621</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sakai, K.</style></author><author><style face="normal" font="default" size="100%">Fujimoto, M.</style></author><author><style face="normal" font="default" size="100%">Ueda, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">II Dep. Surg., Osaka City Univ. Med. Sch., Osaka</style></auth-address><titles><title><style face="normal" font="default" size="100%">Clinical evaluation of MOM in the treatment of skin and soft tissue infections - a double blind comparison of MOM and midecamycin</style></title><secondary-title><style face="normal" font="default" size="100%">Chemotherapy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Chemotherapy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">231-253</style></pages><volume><style face="normal" font="default" size="100%">31</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">midecamycin</style></keyword><keyword><style face="normal" font="default" size="100%">new drug</style></keyword><keyword><style face="normal" font="default" size="100%">adverse drug reaction</style></keyword><keyword><style face="normal" font="default" size="100%">clinical article</style></keyword><keyword><style face="normal" font="default" size="100%">diarrhea</style></keyword><keyword><style face="normal" font="default" size="100%">drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">gastrointestinal toxicity</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">intoxication</style></keyword><keyword><style face="normal" font="default" size="100%">midecamycin diacetate</style></keyword><keyword><style face="normal" font="default" size="100%">oral drug administration</style></keyword><keyword><style face="normal" font="default" size="100%">rash</style></keyword><keyword><style face="normal" font="default" size="100%">safety</style></keyword><keyword><style face="normal" font="default" size="100%">skin</style></keyword><keyword><style face="normal" font="default" size="100%">soft tissue</style></keyword><keyword><style face="normal" font="default" size="100%">soft tissue infection</style></keyword><keyword><style face="normal" font="default" size="100%">stomach</style></keyword><keyword><style face="normal" font="default" size="100%">stomach pain</style></keyword><keyword><style face="normal" font="default" size="100%">therapy</style></keyword><keyword><style face="normal" font="default" size="100%">vertigo</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1983</style></year></dates><isbn><style face="normal" font="default" size="100%">0009-3165</style></isbn><abstract><style face="normal" font="default" size="100%">A double-blind comparative study of 9,3&apos;&apos;-diacetyl-midecamycin (MOM) and midecamycin (MDM) was conducted to evaluate the therapeutic efficacy and safety in the treatment of skin and soft tissue infections. Either 600 mg of MOM or 1,200 mg of MDM per day was administered orally to patients in three separate doses for a period of 7 consecutive days. Of the 215 cases (105 cases of MOM group and 110 cases of MDM group) recruited in this trial, 186 cases (89 cases of MOM group and 97 cases of MDM group) were adopted by the committee members for the evaluation of therapeutic efficacy and usefulness and 190 cases (91 cases of MOM group and 99 cases of MDM group) were adopted for the evaluation of side effects. The backgrounds of both patient groups were almost similar. The results obtained were as follows: Overall clinical effectiveness: Of the 89 patients treated with MOM, excellent clinical responses were obtained in 37 cases, good in 30, poor in 22 (efficacy rate was 75.3%), and of the 97 patients treated with MDM, excellent responses were obtained in 38, good in 26, poor in 33 (efficacy rate 66.0%). There was no statistically significant difference between the two groups. Clinical effectiveness classified by initial severity and bacteriological efficacy: There was no significant difference between the two groups in the clinical effectiveness classified by initial severity and in the bacteriological efficacy. There was no significant difference between the two groups in the usefulness of the drugs. In patients without combined surgical treatment, therapeutic efficacy of MOM was found to be significantly superior to that of MDM. However, in patients who received surgical treatment, no statistically significant difference was noticed between the two groups. We suggest that MOM is more bacteriocidal than MDM. Side effects were noticed in 2 patients out of 89 treated with MOM (2.2%) and in 3 patients out of 97 treated with MDM (3.0%), and another two patients developed some abnormal laboratory findings. But these undesirable reactions were mild, and developed no significant difference between the two groups in the incidence of side effects. There was also no clear causal relationship between these laboratory findings and the drugs. Conclusively, 600 mg of MOM per day is anticipative of the same or a better clinical efficacy and usefulness as compared with that of 1,200 mg of MDM per day in the treatment of skin and soft tissue infections. MOM is also considered a drug with low incidence of side effects and a safe and useful one.</style></abstract><label><style face="normal" font="default" size="100%">Included by both</style></label><notes><style face="normal" font="default" size="100%">L13161120&#xD;1983-05-19</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L13161120&amp;from=export</style></url></related-urls></urls><research-notes><style face="normal" font="default" size="100%">Can we use Table 8? Cellulitis is not the majority </style></research-notes></record><record><database name="Cellulitis response search RCTs.enl" path="C:\Users\Conno\Downloads\Cellulitis response search RCTs.enl">Cellulitis response search RCTs.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>622</rec-number><foreign-keys><key app="EN" db-id="v99pw0vtkz9rrlevf57xs9tlx05r25wfrpzz">622</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Tack, K. J.</style></author><author><style face="normal" font="default" size="100%">Littlejohn, T. W.</style></author><author><style face="normal" font="default" size="100%">Mailloux, G.</style></author><author><style face="normal" font="default" size="100%">Wolf, M. M.</style></author><author><style face="normal" font="default" size="100%">Keyserling, C. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">K.J. Tack, Parke-Davis Pharmaceutical Research, 2800 Plymouth Road, Ann Arbor, MI 48105, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cefdinir versus cephalexin for the treatment of skin and skin-structure infections</style></title><secondary-title><style face="normal" font="default" size="100%">Clinical Therapeutics</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Clinical Therapeutics</style></full-title></periodical><pages><style face="normal" font="default" size="100%">244-256</style></pages><volume><style face="normal" font="default" size="100%">20</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">cefalexin</style></keyword><keyword><style face="normal" font="default" size="100%">cefdinir</style></keyword><keyword><style face="normal" font="default" size="100%">adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">controlled clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">diarrhea</style></keyword><keyword><style face="normal" font="default" size="100%">dose response</style></keyword><keyword><style face="normal" font="default" size="100%">double blind procedure</style></keyword><keyword><style face="normal" font="default" size="100%">drug elimination</style></keyword><keyword><style face="normal" font="default" size="100%">drug half life</style></keyword><keyword><style face="normal" font="default" size="100%">drug safety</style></keyword><keyword><style face="normal" font="default" size="100%">drug tolerability</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">headache</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">minimum inhibitory concentration</style></keyword><keyword><style face="normal" font="default" size="100%">multicenter study</style></keyword><keyword><style face="normal" font="default" size="100%">nausea</style></keyword><keyword><style face="normal" font="default" size="100%">oral drug administration</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial</style></keyword><keyword><style face="normal" font="default" size="100%">rash</style></keyword><keyword><style face="normal" font="default" size="100%">skin abscess</style></keyword><keyword><style face="normal" font="default" size="100%">skin infection</style></keyword><keyword><style face="normal" font="default" size="100%">Staphylococcus aureus</style></keyword><keyword><style face="normal" font="default" size="100%">Streptococcus pyogenes</style></keyword><keyword><style face="normal" font="default" size="100%">vaginitis</style></keyword><keyword><style face="normal" font="default" size="100%">wound infection</style></keyword><keyword><style face="normal" font="default" size="100%">ci 983</style></keyword><keyword><style face="normal" font="default" size="100%">fk 482</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1998</style></year></dates><isbn><style face="normal" font="default" size="100%">0149-2918</style></isbn><abstract><style face="normal" font="default" size="100%">Because of increasing resistance to older antimicrobial agents, newer drugs need to be evaluated for the treatment of skin and skin-structure infections (SSSIs). This double-masked, randomized, comparative, multicenter study enrolled patients aged 13 years or older with SSSIs to receive either cefdinir 300 mg BID or cephalexin 500 mg QID for 10 days. Nine hundred fifty- two patients (474 in the cefdinir group and 478 in the cephalexin group) took part, primarily white males between 18 and 65 years of age. There were two follow-up visits, with efficacy determined at the test-of-cure visit, 7 to 16 clays posttherapy. Many patients were not microbiologically assessable, primarily because of negative cultures at study admission. Patients who required surgical intervention (eg, incision and drainage) at the site of infection more than 24 hours after the initiation of drug therapy were defined as treatment failures. Significantly more isolated pathogens were resistant to cephalexin than to cefdinir. In the 178 efficacy-assessable cefdinir-treated patients, the rate of pathogen eradication was 93% (200/215), and the rate of successful clinical response was 88% (157/178), compared with 89% (221/247) and 87% (177/204), respectively, in the 204 efficacy-assessable cephalexin-treated patients. Using confidence-interval analysis, the microbiologic and clinical response rates of the cefdinir- treated patients were statistically equivalent to those of the cephalexin- treated patients. At the follow-up visits, patients were questioned about any adverse events occurring since their previous visit. Any untoward symptom occurring during or within 2 days after completion of drug treatment was considered an adverse reaction if the investigator judged it to be definitely, probably, or possibly related to the study drug. One hundred twenty-three (26%) cefdinir treated patients and 77 (16%) cephalexin-treated patients experienced at least one adverse reaction, a statistically significant difference. Study drug was discontinued for adverse reactions in 20 (4%) cefdinir-treated patients and 13 (3%) cephalexin-treated patients; in the two groups, 10 and 7 patients, respectively, were discontinued for diarrhea. Cefdinir taken BID was as effective as cephalexin taken QID in the treatment of mild-to-moderate SSSIs and was well tolerated by most patients. The increased antibacterial activity of cefdinir must be balanced against the higher rate of diarrhea seen in patients treated with this drug.</style></abstract><label><style face="normal" font="default" size="100%">Included by both</style></label><notes><style face="normal" font="default" size="100%">L28241745&#xD;1998-07-07</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L28241745&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1016/S0149-2918(98)80088-X</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">ci 983&#xD;fk 482</style></custom1><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/S0149-2918(98)80088-X</style></electronic-resource-num><research-notes><style face="normal" font="default" size="100%">Useful info in table 5 - but cellulitis is not the majority </style></research-notes></record><record><database name="Cellulitis response search RCTs.enl" path="C:\Users\Conno\Downloads\Cellulitis response search RCTs.enl">Cellulitis response search RCTs.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>623</rec-number><foreign-keys><key app="EN" db-id="v99pw0vtkz9rrlevf57xs9tlx05r25wfrpzz">623</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinen, J.</style></author><author><style face="normal" font="default" size="100%">Hudson, B.</style></author><author><style face="normal" font="default" size="100%">Chan, B.</style></author><author><style face="normal" font="default" size="100%">Fernandes, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">J. Vinen, Department of Emergency Medicine, Royal North Shore Hospital, St Leonards, NSW 2065, Australia</style></auth-address><titles><title><style face="normal" font="default" size="100%">A randomised comparative study of once-daily ceftriaxone and 6-hourly flucloxacillin in the treatment of moderate to severe cellulitis. Clinical efficacy, safety and pharmacoeconomic implications</style></title><secondary-title><style face="normal" font="default" size="100%">Clinical Drug Investigation</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Clinical Drug Investigation</style></full-title></periodical><pages><style face="normal" font="default" size="100%">221-225</style></pages><volume><style face="normal" font="default" size="100%">12</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">ceftriaxone</style></keyword><keyword><style face="normal" font="default" size="100%">flucloxacillin</style></keyword><keyword><style face="normal" font="default" size="100%">abdominal pain</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">aged</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">cellulitis</style></keyword><keyword><style face="normal" font="default" size="100%">cholestatic hepatitis</style></keyword><keyword><style face="normal" font="default" size="100%">clinical article</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">diarrhea</style></keyword><keyword><style face="normal" font="default" size="100%">drug efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">drug safety</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">intravenous drug administration</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">nausea</style></keyword><keyword><style face="normal" font="default" size="100%">pharmacoeconomics</style></keyword><keyword><style face="normal" font="default" size="100%">priority journal</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial</style></keyword><keyword><style face="normal" font="default" size="100%">Staphylococcus aureus</style></keyword><keyword><style face="normal" font="default" size="100%">vagina candidiasis</style></keyword><keyword><style face="normal" font="default" size="100%">vomiting</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1996</style></year></dates><isbn><style face="normal" font="default" size="100%">1173-2563</style></isbn><abstract><style face="normal" font="default" size="100%">In a study comparing flucloxacillin (1 g every 6 hours intravenously), as standard treatment for moderate to severe cellulitis, with ceftriaxone (1 g once daily intravenously), ceftriaxone was found to be an effective alternative to flucloxacillin without the associated risk of serious cholestatic hepatitis. Forty-seven evaluable patients, 24 in the ceftriaxone group and 23 in the flucloxacillin group, were evaluated in this prospective randomised study examining clinical efficacy, safety and duration of hospitalisation. 22 of 23 (96%) patients in the ceftriaxone group achieved clinical success (clinical cure and improvement), while 16 of 22 (70%) flucloxacillin patients were considered a clinical success (clinical cure and improvement). Baseline bacteriology was not performed in the single patient who did not respond to ceftriaxone, while 5 of the 6 patients who did not respond to flucloxacillin had a negative baseline culture. The remaining flucloxacillin failure was infected with Staphylococcus aureus, which persisted at the post-treatment evaluation. All other pathogens isolated at baseline in both treatment arms were eradicated at the post-treatment bacteriological evaluation. No serious or unexpected adverse events were reported in either group. Because it requires only once-daily administration, ceftriaxone made it possible for some patients to be treated as outpatients, resulting in an average reduction of 3.04 hospital bed-days, while at the same time being as efficacious as flucloxacillin.</style></abstract><label><style face="normal" font="default" size="100%">Included by both</style></label><notes><style face="normal" font="default" size="100%">L26393414&#xD;1996-12-05</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L26393414&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.2165/00044011-199612050-00001</style></url><url><style face="normal" font="default" size="100%">https://link.springer.com/article/10.2165/00044011-199612050-00001</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.2165/00044011-199612050-00001</style></electronic-resource-num><research-notes><style face="normal" font="default" size="100%">Moderate to severe cellulitis?? </style></research-notes></record><record><database name="Cellulitis response search RCTs.enl" path="C:\Users\Conno\Downloads\Cellulitis response search RCTs.enl">Cellulitis response search RCTs.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>624</rec-number><foreign-keys><key app="EN" db-id="v99pw0vtkz9rrlevf57xs9tlx05r25wfrpzz">624</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zeglaoui, F.</style></author><author><style face="normal" font="default" size="100%">Dziri, C.</style></author><author><style face="normal" font="default" size="100%">Mokhtar, I.</style></author><author><style face="normal" font="default" size="100%">Ezzine, N.</style></author><author><style face="normal" font="default" size="100%">Kharfi, M.</style></author><author><style face="normal" font="default" size="100%">Zghal, M.</style></author><author><style face="normal" font="default" size="100%">Fazaa, B.</style></author><author><style face="normal" font="default" size="100%">Kamoun, M. R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology, Hopital Charles Nicolle Boulevard du 9 Avril 1006, Tunis, Tunisia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Intramuscular bipenicillin vs. intravenous penicillin in the treatment of erysipelas in adults: randomized controlled study</style></title><secondary-title><style face="normal" font="default" size="100%">J Eur Acad Dermatol Venereol</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Eur Acad Dermatol Venereol</style></full-title></periodical><pages><style face="normal" font="default" size="100%">426-8</style></pages><volume><style face="normal" font="default" size="100%">18</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Bacterial Agents/*administration &amp; dosage/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Administration Schedule</style></keyword><keyword><style face="normal" font="default" size="100%">Erysipelas/*drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Injections, Intramuscular/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Injections, Intravenous/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Penicillin G/*administration &amp; dosage/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Penicillin G Procaine/*administration &amp; dosage/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Failure</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2004</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0926-9959 (Print)&#xD;0926-9959</style></isbn><abstract><style face="normal" font="default" size="100%">The objective of the study was to evaluate the efficacy of intramuscular penicillin: mixture of benzyl penicillin and procain penicillin (2 MU x 2 times daily) and intravenous benzyl penicillin (4 MU x 6 times daily) in the treatment of hospitalized adult patients with erysipelas. A prospective randomized unicentric trial was conducted. In total, 112 patients entered the study; 57 in the intramuscular group and 55 patients in the intravenous group completed the trial. The failure rate was 14% for intramuscular group and 20% for the intravenous group (P = 0.40). Local complications such as of the leg abscesses were observed in the two groups (intravenous 9.1%, intramuscular 7%; P = 0477). Of the patients treated with intravenous benzyl penicillin, 25.5% presented complications related to the route (venitis). Intramuscular penicillin should be considered an effective and well-tolerated treatment of erysipelas in adult patients.</style></abstract><label><style face="normal" font="default" size="100%">Included by both</style></label><notes><style face="normal" font="default" size="100%">Zeglaoui, F&#xD;Dziri, C&#xD;Mokhtar, I&#xD;Ezzine, N&#xD;Kharfi, M&#xD;Zghal, M&#xD;Fazaa, B&#xD;Kamoun, M R&#xD;Clinical Trial&#xD;Comparative Study&#xD;Journal Article&#xD;Randomized Controlled Trial&#xD;England</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1468-3083.2004.00938.x?download=true</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/j.1468-3083.2004.00938.x&#xD;10.1111/j.1468-3083.2004.00938.x.</style></electronic-resource-num><research-notes><style face="normal" font="default" size="100%">Looks at treatment failure </style></research-notes></record></records></xml>